- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02442375
Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity (UPGRADE-RT)
Uniform FDG-PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE-RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma
The objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective radiation dose and introduction of an intermediate dose-level in the treatment of head and neck cancer will results in less radiation sequelae and improved quality of life after treatment whilst the recurrence rate in electively irradiated lymph nodes should not be compromised.
A summary of the study protocol can be found here: http://rdcu.be/qgMv
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- VU University Medical Center Amsterdam
-
Arnhem, Netherlands
- Radiotherapiegroep, Arnhem
-
Maastricht, Netherlands
- MAASTRO clinic, Maastricht
-
Nijmegen, Netherlands
- Radboud University Nijmegen Medical Center
-
Utrecht, Netherlands
- University Medical Center Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newly diagnosed tumours classified as stage T2-4 N0-2 (TNM 7th edition 2009) located in the larynx, oropharynx or hypopharynx (unknown primary and oral cavity are not eligible)
- Histopathological diagnosis of invasive squamous cell carcinoma in the primary tumour
- Decision for curative intent external beam radiotherapy with elective treatment of the neck made by a multidisciplinary head-and-neck oncology team. The patient must be expected to complete the treatment.
- Radiotherapy planned to start within 6 weeks from baseline imaging of tumour assessment
- No distant metastasis (M0) (TNM 7th edition 2009)
- WHO performance status 0-2
- ≥ 18 years of age
- Written informed consent
Exclusion Criteria:
- Concomitant chemotherapy or EGFR inhibitors for this tumour.
- Primary tumour of the oral cavity or unknown primary tumour
- Prior or current anticancer treatment to the head and neck area (e.g. radical attempted or tumour reductive surgery, neo-adjuvant or concomitant chemotherapy, EGFR inhibitors or radiotherapy), except for endoscopic glottic laser micro surgery.
- Current participation in any other oncologic interventional clinical study for this tumor.
- Uncontrolled diabetes mellitus.
- Known or suspected HIV infection.
- History of previous malignancy within the last 3 years, with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, basal/squamous cell carcinoma of the skin, and other non-invasive malignancies (e.g. in situ carcinomas)..
- Any condition (somatic, psychological, familial, sociological or geographical) rendering the patient unable to understand or complete questionnaires.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard dose prescription
|
|
Experimental: FDG-PET guided gradient dose prescription
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity: normalcy of diet (score of the performance status scale for head and neck cancer patients)
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: recurrence in electively irradiated lymph nodes
Time Frame: 24 months
|
A Kaplan-Meier estimate will be calculated
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute toxicity (common toxicity criteria v2.0)
Time Frame: up to 3 months
|
up to 3 months
|
|
Late toxicity: swallowing function (water swallowing test)
Time Frame: 3, 12 and 24 months
|
3, 12 and 24 months
|
|
Late toxicity: salivary gland function (stimulated flow rates)
Time Frame: 3, 12 and 24 months
|
3, 12 and 24 months
|
|
Late toxicity: thyroid gland function (thyroid stimulating hormone blood test)
Time Frame: 3, 12 and 24 months
|
3, 12 and 24 months
|
|
Quality of life (EORTC QLQ-C30 and QLQ-H&N35 questionnaires)
Time Frame: 3, 6, 12 and 24 months
|
3, 6, 12 and 24 months
|
|
Xerostomia related quality of life (GRIX questionnaire)
Time Frame: 3, 6, 12 and 24 months
|
3, 6, 12 and 24 months
|
|
Dysphagia related quality of life (SWAL-QOL questionnaire)
Time Frame: 3, 6, 12 and 24 months
|
3, 6, 12 and 24 months
|
|
Loco-regional control
Time Frame: 24 months
|
A Kaplan-Meier estimate will be calculated
|
24 months
|
Overall survival
Time Frame: 24 months
|
A Kaplan-Meier estimate will be calculated
|
24 months
|
Disease specific survival
Time Frame: 24 months
|
A Kaplan-Meier estimate will be calculated
|
24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Prof. Dr. J.H.A.M. Kaanders, Radboud University Nijmegen Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPGRADE-RT v3.5 dd20201201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on standard dose prescription
-
University of PortsmouthPortsmouth Hospitals NHS TrustCompleted
-
University of TennesseeCompleted
-
The University of Texas Health Science Center,...Brighter Bites and Humana FoundationNot yet recruiting
-
The University of Texas Health Science Center,...American Heart AssociationNot yet recruitingNutritional Deficiency in PregnancyUnited States
-
Tel Aviv UniversityRecruiting
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
Tata Medical CenterCompletedMalignant Neoplasm of Oropharynx Stage III | Malignant Neoplasm of Larynx Stage III | Malignant Neoplasm of Hypopharynx Stage III | Malignant Neoplasm of Oropharynx Stage IVa | Malignant Neoplasm of Oropharynx Stage IVb | Malignant Neoplasm of Larynx Stage IV | Malignant Neoplasm of Hypopharynx... and other conditionsIndia
-
Pavol Jozef Safarik UniversityUniversity of GroningenWithdrawnCardiovascular DiseasesSlovakia
-
Alfonso Gomez-IturriagaHospital de CrucesUnknown
-
Masaryk Memorial Cancer InstituteRecruiting